

# Neil Parrott

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10509593/publications.pdf>

Version: 2024-02-01

35  
papers

2,308  
citations

257450

24  
h-index

361022

35  
g-index

38  
all docs

38  
docs citations

38  
times ranked

1919  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of the Success of High-Throughput Physiologically Based Pharmacokinetic (HT-PBPK) Modeling Predictions to Inform Early Drug Discovery. <i>Molecular Pharmaceutics</i> , 2022, 19, 2203-2216.	4.6	17
2	Understanding Mechanisms of Food Effect and Developing Reliable PBPK Models Using a Middle-out Approach. <i>AAPS Journal</i> , 2021, 23, 12.	4.4	23
3	Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. <i>Advanced Drug Delivery Reviews</i> , 2021, 171, 289-331.	13.7	84
4	PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5- $\alpha$ -Diphospho-glucuronosyltransferase Substrates. <i>Pharmaceutics</i> , 2021, 13, 1325.	4.5	9
5	Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective. <i>AAPS Journal</i> , 2020, 22, 123.	4.4	53
6	Construction and Verification of Physiologically Based Pharmacokinetic Models for Four Drugs Majorly Cleared by Glucuronidation: Lorazepam, Oxazepam, Naloxone, and Zidovudine. <i>AAPS Journal</i> , 2020, 22, 128.	4.4	16
7	Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib. <i>AAPS Journal</i> , 2020, 22, 78.	4.4	35
8	The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 134, 31-59.	4.0	224
9	Impact of regional differences along the gastrointestinal tract of healthy adults on oral drug absorption: An UNGAP review. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 134, 153-175.	4.0	146
10	Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies. <i>Clinical Pharmacokinetics</i> , 2019, 58, 727-746.	3.5	93
11	Investigating Oral Absorption of Carbamazepine in Pediatric Populations. <i>AAPS Journal</i> , 2017, 19, 1864-1877.	4.4	19
12	The great barrier belief: The blood-brain barrier and considerations for juvenile toxicity studies. <i>Reproductive Toxicology</i> , 2017, 72, 129-135.	2.9	28
13	Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. <i>Pharmaceutical Research</i> , 2016, 33, 2565-2579.	3.5	14
14	Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans. <i>Xenobiotica</i> , 2016, 46, 667-676.	1.1	5
15	The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development. <i>Proteomics - Clinical Applications</i> , 2015, 9, 732-744.	1.6	27
16	Quantitative ADME Proteomics – CYP and UGT Enzymes in the Beagle Dog Liver and Intestine. <i>Pharmaceutical Research</i> , 2015, 32, 74-90.	3.5	47
17	Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: Influence of time between substrate and inducer administration. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 56, 1-15.	4.0	65
18	Applications of a 7-day Caco-2 cell model in drug discovery and development. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 56, 120-130.	4.0	38

#	ARTICLE	IF	CITATIONS
19	Physiologically Based Absorption Modelling to Predict the Impact of Drug Properties on Pharmacokinetics of Bitopertin. <i>AAPS Journal</i> , 2014, 16, 1077-1084.	4.4	29
20	Pharmacokinetics of Paracetamol in Göttingen Minipigs: In Vivo Studies and Modeling to Elucidate Physiological Determinants of Absorption. <i>Pharmaceutical Research</i> , 2014, 31, 2696-2707.	3.5	28
21	A Physiologically Based Pharmacokinetic Model of the Minipig: Data Compilation and Model Implementation. <i>Pharmaceutical Research</i> , 2013, 30, 1-15.	3.5	75
22	In Vitro to in Vivo Extrapolation and Physiologically Based Modeling of Cytochrome P450 Mediated Metabolism in Beagle Dog Gut Wall and Liver. <i>Molecular Pharmaceutics</i> , 2013, 10, 1388-1399.	4.6	19
23	Physiologically Based Pharmacokinetic Modelling to Predict Single- and Multiple-Dose Human Pharmacokinetics of Bitopertin. <i>Clinical Pharmacokinetics</i> , 2013, 52, 673-683.	3.5	14
24	Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates – An evaluation and case study using GastroPlus®, <sup>®</sup> . <i>European Journal of Pharmaceutical Sciences</i> , 2012, 47, 375-386.	4.0	63
25	Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions. <i>Future Medicinal Chemistry</i> , 2012, 4, 681-693.	2.3	10
26	Mass Spectrometry-Based Quantification of CYP Enzymes to Establish In Vitro/In Vivo Scaling Factors for Intestinal and Hepatic Metabolism in Beagle Dog. <i>Pharmaceutical Research</i> , 2012, 29, 1832-1842.	3.5	29
27	Development of a Physiologically Based Model for Oseltamivir and Simulation of Pharmacokinetics in Neonates and Infants. <i>Clinical Pharmacokinetics</i> , 2011, 50, 613-623.	3.5	100
28	Applications of Physiologically Based Absorption Models in Drug Discovery and Development. <i>Molecular Pharmaceutics</i> , 2008, 5, 760-775.	4.6	107
29	A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 2006, 45, 511-542.	3.5	301
30	Predicting Pharmacokinetic Food Effects Using Biorelevant Solubility Media and Physiologically Based Modelling. <i>Clinical Pharmacokinetics</i> , 2006, 45, 1213-1226.	3.5	131
31	A strategy for preclinical formulation development using GastroPlus®, <sup>®</sup> as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 27, 91-99.	4.0	105
32	Application of Full Physiological Models for Pharmaceutical Drug Candidate Selection and Extrapolation of Pharmacokinetics to Man. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2005, 96, 193-199.	2.5	91
33	An Evaluation of the Utility of Physiologically Based Models of Pharmacokinetics in Early Drug Discovery. <i>Journal of Pharmaceutical Sciences</i> , 2005, 94, 2327-2343.	3.3	100
34	Interspecies Scaling. , 2004, , 133-175.		3
35	Prediction of intestinal absorption: comparative assessment of gastroplus®, <sup>®</sup> and idea®, <sup>®</sup> . <i>European Journal of Pharmaceutical Sciences</i> , 2002, 17, 51-61.	4.0	159